In a major advancement for HIV treatment, Gilead Sciences and Merck have announced positive topline results from two pivotal Phase 3 clinical trials evaluating an investigational once-weekly oral HIV therapy that combines islatravir and lenacapavir. The promising findings bring the healthcare industry one step closer to introducing what could become the world's first long-acting oral HIV treatment taken just once a week.
The Phase 3 studies, known as ISLEND-1 and ISLEND-2, successfully met their primary efficacy endpoints at Week 48. According to the companies, the once-weekly single-tablet regimen demonstrated effectiveness in maintaining viral suppression among people living with HIV, performing comparably to currently available daily treatment options.
The investigational therapy combines two innovative antiretroviral agents with different mechanisms of action. Islatravir, developed by Merck, is a next-generation nucleoside analog designed to inhibit HIV replication, while lenacapavir, developed by Gilead, is a first-in-class capsid inhibitor that targets multiple stages of the HIV lifecycle. Together, they offer a novel approach to long-term HIV management.
The concept of reducing dosing frequency from daily pills to a once-weekly tablet could significantly improve treatment convenience, adherence, and quality of life for many patients. Healthcare experts have long recognized that less frequent dosing options may help reduce treatment fatigue and provide greater flexibility for people living with HIV.
The positive Phase 3 results build upon encouraging earlier studies that demonstrated the ability of the islatravir-lenacapavir combination to maintain viral suppression while maintaining a favorable safety profile.
Both companies have indicated that detailed data from the studies will be presented at upcoming scientific meetings and will support future regulatory submissions. If approved by health authorities, the regimen could represent a significant milestone in HIV treatment by becoming the first once-weekly oral therapy available to patients.
